News
-
-
PRESS RELEASE
NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage
Nanobiotix annonce les premières données de phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage. Taux de contrôle de la maladie de 85% et taux de réponse objective de 69% -
-
-
-
-
PRESS RELEASE
Carcetti Announces Total Gross Proceeds From Financing of Approximately $492 Million Comprised of Upsized Bought Deal Private Placement of $437 Million and Concurrent Non-Brokered Private Placement of Approximately $55 Million
Carcetti Capital Corp. announces an increase in the size of its bought deal private placement offering to approximately $437 million and amendment of terms. Company to acquire Hemlo Gold Mine in Ontario -
-
-
